Navigation Links
Osteotech Receives 13485:2003 ISO Certification; Company Meets International Standards for Medical Device Manufacturing

EATONTOWN, N.J., Feb. 19 /PRNewswire-FirstCall/ -- Osteotech, Inc. (Nasdaq: OSTE), a leader in the emerging field of biologic products for regenerative healing, announced today that it has received ISO 13485:2003 certification for its quality management system. Osteotech received ISO certification for developing, manufacturing and marketing of biologic, biomaterial and device systems for musculoskeletal surgery and the processing of human bone and connective tissue for transplantation. Osteotech's wholly-owned subsidiaries, OST Developpement SA and TB OsteoCentre Bulgaria EAD previously received ISO 9001 certification, and OST also previously received ISO 13485:2003 certification, for their quality management systems.

"We are very pleased to announce that we have received ISO certification for our U.S. quality management system," said Sam Owusu-Akyaw, President and Chief Executive Officer of Osteotech. "The certification reinforces our commitment to maintaining a high quality processing facility and to ensuring the safety of those patients that utilize our products. Receiving the certification is an important milestone as we continue towards our goal to become a leader in regenerative and biologic healing."

Osteotech's facilities in Eatontown, New Jersey and Clermont-Ferrand, France are the processing sites for the Company's allograft tissue grafts utilized in its broad portfolio of therapy-driven products focused on promoting regenerative and biologic healing. To date, Osteotech has successfully processed more than four million tissue grafts worldwide. The Company's advanced technology platforms, all processed at its Eatontown facility, include Grafton(R) DBM and the Plexur(R) Biocomposite family of products as well as the DuraTech(TM) BioRegeneration Matrix, Osteotech's leading product based upon its proprietary human collagen technology platform. Osteotech recently initiated a pivotal clinical trial to evaluate the safety of the DuraTech BioRegeneration Matrix for dura mater repair during craniotomy procedures. During the third and fourth quarters of 2009, the Company intends to file regulatory applications with the United States Food and Drug Administration and with the competent authority in certain other countries to obtain marketing clearance for DuraTech BioRegeneration Matrix.

"ISO certification validates the quality systems we have put in place to ensure the integrity of all of our products," added Greg Cannedy, Vice President of Regulatory Affairs at Osteotech. "Certification of our U.S. facilities complements the ISO certifications received by our European subsidiaries and marks an important step forward in bringing future products, including our DuraTech BioRegeneration Matrix, to market."

About ISO Certification

The International Organization for Standardization ("ISO") is a world-wide federation of national standards bodies. ISO certification is an international standard that specifies a quality management system for the development, production and distribution of medical devices and related services.

About Osteotech

Osteotech, Inc., headquartered in Eatontown, New Jersey, is a global leader in providing OsteoBiologic solutions for regenerative medicine to support surgeons and their patients through the development of innovative therapy-driven products that alleviate pain, promote regenerative and biologic healing and restore function. For further information regarding Osteotech or this press release, please go to Osteotech's website at

Certain statements made throughout this press release that are not historical facts contain forward-looking statements (as such are defined in the Private Securities Litigation Reform Act of 1995) regarding the Company's future plans, objectives and expected performance. Any such forward-looking statements are based on assumptions that the Company believes are reasonable, but are subject to a wide range of risks and uncertainties and, therefore, there can be no assurance that actual results may not differ materially from those expressed or implied by such forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to, the Company's ability to develop and introduce new products, differences in anticipated and actual product and service introduction dates, the ultimate success of those products in the marketplace, the continued acceptance and growth of current products and services, the impact of competitive products and services, the availability of sufficient quantities of suitable donated tissue and the success of cost control and margin improvement efforts. These and other factors that could cause actual results to differ materially from such forward-looking statements are detailed from time to time in the Company's periodic reports filed with the Securities and Exchange Commission. All information in this press release is as of February 19, 2009 and the Company does not intend to update this information.

SOURCE Osteotech, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Osteotech to Present at First Albany Capitals Regenerative Technologies Conference in New York
2. Osteotech Completes Tissue Supply Agreement With LifeNet Health
3. Osteotech Announces Third Quarter Earnings Release and Conference Call Schedule
4. Osteotech Reports 2007 Third Quarter Financial Results; Core Segment Revenue Increased 28%; Gross Margin Improved to 55%; Diluted Earnings Per Share of $.09
5. Osteotech Signs Agreement To Distribute Harvest Technologies BMAC(TM) System
6. Osteotech Engages BioHorizons as Exclusive Distributor to International Dental Market
7. Osteotech Announces the Unexpected Passing of Audit Committee Member Leads to Receipt of Nasdaq Deficiency Letter
8. Osteotech Reports 2008 Second Quarter Diluted Earnings Per Share of $.10 on Revenues of $27.6 Million
9. Osteotech Expands Senior Management Team; New Executives to Drive Sales Force Strategies and Therapy-Based Solutions
10. Lake Elsinore Family Caregiver Receives Free Power Wheelchair From The SCOOTER Store
11. DaVita Receives Civil Complaint
Post Your Comments:
(Date:12/1/2015)... ... December 01, 2015 , ... TCS Healthcare Technologies (TCS), ... population health arenas, is pleased to announce that VIP Care Services, a Caprock ... implemented the ACUITY Complete Care™ Management to back their collaborative catastrophic case management ...
(Date:12/1/2015)... (PRWEB) , ... December 01, 2015 , ... Nurotron Biotechnology ... in its largest order to date. , The order will be from the ... Nurotron’s Venus Cochlear Implant System is an effective solution for children and adults suffering ...
(Date:11/30/2015)... (PRWEB) , ... November 30, 2015 , ... ... Amanda Beard and Brooke Bennett are collaborating with brands across various categories through ... four influential figures make up an elite group of Gold Medal Moms who ...
(Date:11/30/2015)... Garden City, NY (PRWEB) , ... December 01, ... ... (NAPW) honors Dale Jones as a 2015-2016 inductee into its ... for leadership in education. NAPW is the nation’s leading networking organization exclusively for ...
(Date:11/30/2015)... VA (PRWEB) , ... November 30, 2015 , ... ... Research Foundation (Meso Foundation) released information for caregivers and held two webinars on ... are available on demand free of charge at . , With ...
Breaking Medicine News(10 mins):
(Date:11/30/2015)... Nov. 30, 2015  The fee-for-service reimbursement ... U.S. medical imaging is on its way ... care payer-provider contracts are set to phase ... wake, alter provider-vendor relationships. The shift to ... forward new purchasing frameworks in the medical ...
(Date:11/30/2015)... WOODCLIFF LAKE, N.J. and SAN ... Inc. and Arena Pharmaceuticals, Inc. (NASDAQ: ARNA ) ... (FDA) has accepted for filing the New Drug Application ... approved, the extended release formulation will offer patients a ... ® ) is currently approved as ...
(Date:11/30/2015)... and ST. LOUIS , Nov. ... (NASDAQ: ESRX ) today announced an early renewal ... which began in 1999, will now extend through at ... --> After evaluating pharmacy benefit manager capabilities during ... Express Scripts continues to offer the best health plan ...
Breaking Medicine Technology: